Innate Pharma S.A. ADS (IPHA) Stock Price

IPHAStock
$2.27+1.84%52W
Market Cap$253.56M
P/E
PEG Ratio
Div yield
Beta1.02

IPHA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)22.32%
Price vs S&P 500 (4W)15.96%
VGM Score33.52

IPHA Analyst Recommendations

May 2026
Jun 2026
Jul 2026
Aug 2026
4.13
4.13
4.13
4.13

Industry Peers — Biological Products(183)

SymbolValue ScoreGrowth ScoreMomentum ScorePrice
IPHAInnate Pharma S.A. ADS
DFB$2.27
AMGNAmgen IncCCB$442.24
GILDGilead Sciences IncCBB$148.77
MRNAModerna, Inc. Common StockDCA$158.83
ARGXargenx SE American Depositary SharesDAB$1019.49
RVMDRevolution Medicines, Inc. Common StockFA$211.38
BIIBBiogen Inc. Common StockCDB$220.77
BNTXBioNTech SE American Depositary ShareCCB$114.05
NBIXNeurocrine Biosciences IncCBC$153.37
EXELExelixis IncCBB$56.72
HALOHalozyme Therapeutics, Inc.CBA$109.32

About Innate Pharma S.A. ADS

Innate Pharma is a clinical-stage biotechnology company developing cancer immunotherapies using its proprietary ANKET platform and therapeutic antibodies to engage the innate immune system. The company generates revenue through research collaborations and licensing agreements with pharmaceutical partners. Its pipeline includes lacutamab, monalizumab, and several other advanced immunotherapy candidates.